With 1 million new cases and 200,000 children dead each year, Tuberculosis (TB) is now the leading cause of death from infectious diseases for children of all ages globally (UNICEF). ImproViTB is among the first pediatric clinical studies in the Central African region aimed at improving the clinical outcome and quality of life of children with pulmonary tuberculosis through a standard antituberculosis treatment supplemented with vitamin D.
This project is lead by a consortium of research institutions and universities from 4 Central African countries (Republic of Congo, Democratic Republic of Congo, Cameroon and Gabon) and 3 European countries, coordinated by CANTAM (Prof. Francine Ntoumi), the Network of Excellence in clinical research for Central African region.

Leave a Reply

Your email address will not be published. Required fields are marked *

Explore More

Ebola outbreak in Republic Democratic of the Congo: switching from MEURI (Monitored Emergency Use of Unregistered and Investigational Interventions) to a RCT (Randomized Clinical Trial) for 4 experimental medications in the treatment of Ebola Virus Disease

An international research team has begun patient enrollment in a clinical trial testing multiple investigational Ebola therapies in the Democratic Republic of the Congo (DRC). The randomized, controlled trial is

Indirect effects of the COVID-19 pandemic on malaria in Africa

In Africa, pregnant women and young children are the most vulnerable to malaria. However, malaria control interventions and strategies have achivied important results in the last years. COVID-19 has now

Ebola vaccines at a la glance

Ebola vaccine candidates are currently being evaluated in phase I–III clinical trials conducted in Africa, the EU and the US. Although preclinical development of candidate vaccines utilise different platforms, including